A Randomized Double‐Blind Placebo‐Controlled First‐In‐Human Phase 1 Trial of TransCon PTH in Healthy Adults

TransCon PTH is a sustained‐release, essentially inactive prodrug transiently bound to an inert carrier, designed to release PTH(1‐34), and in development for hypoparathyroidism (HP). This phase 1, randomized, placebo‐controlled, single and multiple ascending dose (SAD and MAD, respectively) trial e...

Descripción completa

Detalles Bibliográficos
Autores principales: Karpf, David B, Pihl, Susanne, Mourya, Sanchita, Mortensen, Eva, Kovoor, Eshwari, Markova, Denka, Leff, Jonathan A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328939/
https://www.ncbi.nlm.nih.gov/pubmed/32212275
http://dx.doi.org/10.1002/jbmr.4016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328939/
https://www.ncbi.nlm.nih.gov/pubmed/32212275
http://dx.doi.org/10.1002/jbmr.4016

Ejemplares similares